Sökning: "uveal melanoma"
Visar resultat 1 - 5 av 17 avhandlingar innehållade orden uveal melanoma.
1. Novel immunotherapies for metastatic melanoma - from mouse models towards clinical trials
Sammanfattning : Immunotherapies including checkpoint blockade and adoptive T cell transfer (ACT) show great promise for the treatment of melanoma, with long-term effects in some patients. However, around half of the patients with metastatic malignant melanoma will not be cured with available therapies today, and these patients require other treatment strategies. LÄS MER
2. Isolated regional perfusion for metastases of malignant melanoma - Clinical and experimental studies
Sammanfattning : Background: Isolated regional perfusion is a treatment option mainly for localized metastatic disease. The principle idea is to surgically isolate a region of the body and connect the circulation to a heart-lung machine. A high concentration of a chemotherapeutic agent is then delivered to the tumour, while systemic toxicity is avoided. LÄS MER
3. Uveal melanoma : epidemiological and clinical aspects
Sammanfattning : A major purpose with this thesis was to assess the incidence and mortality rates of uveal melanoma in Sweden during the period 1960 to 1998, using population-based registry data. In total, 2,995 patients (1,541 males and 1,454 females) were diagnosed with uveal melanoma. LÄS MER
4. Translational studies of metastatic melanoma in the era of immunotherapy - from humanized mouse models to clinical trials
Sammanfattning : Immunotherapy with PD-1 inhibitors has transformed the treatment of met-astatic cutaneous mela- noma, and can lead to complete and durable responses in a proportion of patients. However, in around half of the patients, the treatment has little or no effect. LÄS MER
5. Immunological effects of isolated regional perfusion in malignant melanoma
Sammanfattning : Malignant melanoma patients with metastatic disease confined to the limbs or liver may be treated with hyperthermic isolated regional perfusion with a chemotherapeutic agent, most commonly melphalan. This procedure enables much higher tissue concentrations of the chemotherapeutic agent compared with systemic administration. LÄS MER